Omeprazole
| Drug Category | Drug | IHD Dosing |
Administration Timing Around HD Session |
|---|---|---|---|
| Proton Pump Inhibitors | Omeprazole | 20mg PO Q24H | Anytime During HD |
|
Molecular Weight (Da) | Excreted Unchanged (%) | Normal Half-Life (Hours) | ESRD Half-Life (Hours) | Plasma Protein Binding (%) | Volume of Distribution (L/kg) | Dialytic Plasma Clearance (ml/min) | % Dialyzed |
|---|---|---|---|---|---|---|---|
| 345.42 | Negligible | 0.5-1 | Unchanged | 95 | N/A | N/A | 0 (Low flux) |
References:
- Aronoff GR, Bennett WM, Berns JS, Brier ME, Kasbekar N, Mueller BA, et al. Drug Prescribing in Renal Failure. Philadelphia: American College of Physicians;2007.
- DrugBank [Online]. 2013 Feb 06 [cited 2013 Feb 06]; Available from: URL: http://www.drugbank.ca
- Howden CW, Payton CD, Meredith RA , Hughes DMA, Macdougall AI, Reid JL, Forrest JA. Antisecretory effect and oral pharmacokinetics of omeprazole in patients with chronic renal failure. Eur J Clin Pharmacol 1985;28:637-40.
- Omeprazole. In: Lexi-Drugs Online. Hudson (OH): Lexi-Comp, Inc,; [updated 02/06/13; accessed 02/06/13].